Subscribe To

Price Alert Latest News Economic Calendar News

CTIC / CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTIC is undervalued and a strong buy for new investors. The current share price of ~$5.63 does not reflect the potential of outsized returns to patient, long-term investors. Under conservative assumptions, my DCF model shows the equity value of CTIC at $17 per fully diluted share, an ~3.2x ROI from current levels. Read More

Demo Live Account See Partner Details

Content Topics

Biopharma

2x

Potential

Upside

De

Risked

Asset

De risked

Stock

CTIC

Posted: May 4 2022, 18:56

Author Name: Seeking Alpha

CTIC News

By Proactive Investors
May 10, 2023

CTI BioPharma skyrockets on acquisition by Sobi

CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orpha

By The Motley Fool
May 10, 2023

Why Shares of CTI BioPharma Are Soaring Wednesday

CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its c

By InvestorPlace
May 10, 2023

Why Is CTI BioPharma (CTIC) Stock Up 85% Today?

CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agre

By Barrons
May 10, 2023

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.

By Market Watch
May 10, 2023

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a d

By PRNewsWire
May 1, 2023

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commer

By Seeking Alpha
April 21, 2023

VONJO Keeps CTI BioPharma A Buy

VONJO Keeps CTI BioPharma A Buy.

By PRNewsWire
April 12, 2023

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.